Skip to Main Content

Paper Details

The Ewing Family of Tumors Relies on BCL-2 and BCL-X to Escape PARP Inhibitor Toxicity.
Clinical Cancer Research
21
2019
-FLI1 t(11;22)(q24;12) translocation, BCL-2, BCL-2/XL, BCL-XL, EWS, EWSR1, Ewing Family of Tumors, Ewing sarcoma, Ewing sarcoma cell lines, Ewing sarcoma cells, Ewing sarcoma tumors, FLI1, PARP, PDX, PDXs, cell line xenograft models, cell lines, chemotherapy, chemotherapy-resistant cells, matched cell line pair, navitoclax, olaparib, patient, patients, tumor, venetoclax
Author NameAffiliation
Cyril H BenesMassachusetts General Hospital Cancer Center, Harvard Medical School
  • 1 - 1

Datasets

Release 1.2